Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control‐ IQ and MiniMed 780G according to patient characteristics
Main finding · TIRResult — go to the resultDifference 6.4 95% CI 3.4–9.5Authors' conclusion
MiniMed 780G is associated with moderate metabolic superiority compared to Control-IQ, without interaction with patient characteristics. These results suggest that neither model is more appropriate for certain populations, particularly patients without carbohydrate counting practice.
Study context
- Population
- Patients aged ≥16 with T1D started on MiniMed 780G or Control-IQ between January 2021 and October 2022 and continued ≥12 months; 58% women; mean age 39 ± 15 years; HbA1c 8.7 ± 1.8%221 propensity score-matched
- Participants
- 245 patients
- Exposure
- MiniMed 780G vs Control-IQ
- MiniMed 780Gn = 67
- Control-IQn = 178reference
- Outcome
- TIR
- Follow-up
- 12 months
Methodological detailssingle-centre, propensity score matching
- Single-centre
- Propensity score matching
Main finding
As reported in the abstract
Difference
6.4
95% CI 3.4–9.5
MiniMed 780Gvs Control-IQ
difference 6.4 (95% CI 3.4–9.5)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Difference (95% CI) | |
|---|---|---|
| GMI · 12 months | −0.42 (−0.59 to −0.25) | |
| CV · 12 months | −2.12 (−3.68 to −0.55) | |
| TBR · 12 months | −0.04 (−0.47; +0.40) | |
| −4−202Difference (linear scale) |
12-month TIR difference across subgroups
- TIR difference consistent across subgroups, including baseline carbohydrate counting
Original publication
Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control‐ IQ and MiniMed 780G according to patient characteristics. Diabetes Obes Metab. Published 17 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →